Monthly
US$200
Billed every month
Oseltamivir Phosphate For Oral Suspension(磷酸奥司他韦干混悬剂)
Companies, stages and changes, with each record available on this page.
Last 90 days: Accepted: 1 applicationNo longer listed under review: 1 application
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders49View records ↓
Under-review filings2View records ↓
This year’s generic filers2View records ↓
NHSA approval numbers39View records ↓
API companies with A status33View records ↓
Chemical-drug catalogue
Loaded records: 49 holders; 0 in the quality-and-efficacy consistency-evaluation category, and 49 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| 澳美制药（海南）有限公司 | 澳美制药（海南）有限公司 | 国药准字H20265380 | 2026/07/28 | 0.36g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江西药都仁和制药有限公司 | 江西药都仁和制药有限公司 | 国药准字H20264737 | 2026/06/10 | 0.36g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 广州白云山医药集团股份有限公司白云山制药总厂 | 中山万汉制药有限公司 | 国药准字H20264504 | 2026/05/27 | 0.36g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东百诺医药股份有限公司 | 南昌立健药业有限公司 | 国药准字H20263971 | 2026/04/14 | 0.36g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 安徽济人药业股份有限公司 | 安徽济人药业股份有限公司 | 国药准字H20263028 | 2026/01/05 | 0.36g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江普洛康裕制药有限公司 | 浙江普洛康裕制药有限公司 | 国药准字H20256273 | 2025/12/16 | 0.36g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东新华制药股份有限公司 | 新华制药（高密）有限公司 | 国药准字H20256303 | 2025/12/16 | 0.36g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 哈药集团制药六厂 | 哈药集团技术中心 | 国药准字H20255698 | 2025/10/14 | 0.36g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南葫芦娃药业集团股份有限公司 | 海南葫芦娃药业集团股份有限公司 | 国药准字H20255455 | 2025/09/09 | 0.36g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 福建省闽东力捷迅药业股份有限公司 | 福建省闽东力捷迅药业股份有限公司 | 国药准字H20254807 | 2025/07/08 | 0.36g（按C16H28N2O4算） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 恒昌（广州）新药研究有限公司 | 武汉海特生物制药股份有限公司 | 国药准字H20254584 | 2025/06/17 | 0.36g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 葵花药业集团（衡水）得菲尔有限公司 | 葵花药业集团（衡水）得菲尔有限公司 | 国药准字H20253868 | 2025/04/15 | 0.36g （按C16H28N2O4计) | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 石药集团中诺药业（石家庄）有限公司 | 石药集团中诺药业（石家庄）有限公司 | 国药准字H20253827 | 2025/04/08 | 0.36g （按C16H28N2O4计) | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 济南同路医药科技发展有限公司 | 山西同达药业有限公司 | 国药准字H20253826 | 2025/04/08 | 0.36g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 宏越科技（湖州）有限公司 | 山西同达药业有限公司 | 国药准字H20253829 | 2025/04/08 | 0.36g （按C16H28N2O4计) | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏加友药业集团有限公司 | 武汉海特生物制药股份有限公司 | 国药准字H20253775 | 2025/04/01 | 0.36g （按C16H28N2O4计) | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 国药集团致君（深圳）制药有限公司 | 武汉海特生物制药股份有限公司 | 国药准字H20253530 | 2025/03/04 | 0.36g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 福建省宝诺医药研发有限公司 | 江苏万高药业股份有限公司 | 国药准字H20253138 | 2025/01/14 | 0.36g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 保定天浩制药有限公司 | 天津汉瑞药业有限公司 | 国药准字H20253060 | 2025/01/02 | 0.36g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 广东万方药业科技有限公司 | 博瑞制药（苏州）有限公司 | 国药准字H20249619 | 2024/12/01 | 0.36g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 北京斯利安药业有限公司 | 北京斯利安药业有限公司 | 国药准字H20249550 | 2024/12/01 | 0.36g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 华润三九医药股份有限公司 | 天津汉瑞药业有限公司 | 国药准字H20249097 | 2024/10/16 | 0.36g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏诺泰澳赛诺生物制药股份有限公司 | 天津汉瑞药业有限公司 | 国药准字H20244919 | 2024/09/19 | 0.36g（按C16H28N4O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东朗诺制药有限公司 | 山东朗诺制药有限公司 | 国药准字H20244903 | 2024/09/19 | 0.36g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏正大清江制药有限公司 | 江苏正大清江制药有限公司 | 国药准字H20244748 | 2024/08/27 | 0.36g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江高跖医药科技股份有限公司 | 山西同达药业有限公司 | 国药准字H20244434 | 2024/07/09 | 0.36g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江普利药业有限公司 | 浙江普利药业有限公司 | 国药准字H20244240 | 2024/06/28 | 0.36g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 四川子仁制药有限公司 | 四川子仁制药有限公司 | 国药准字H20244155 | 2024/06/25 | 0.36g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江兄弟药业有限公司 | 华益药业科技（安徽）有限公司 | 国药准字H20244141 | 2024/06/25 | 0.36g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南斯达制药有限公司 | 天津汉瑞药业有限公司 | 国药准字H20243816 | 2024/05/28 | 0.36g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 乐普制药科技有限公司 | 乐普制药科技有限公司 | 国药准字H20243080 | 2024/01/23 | 0.36g（按C16H28N2O4 计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 哈尔滨华瑞生化药业有限责任公司 | 哈尔滨华瑞生化药业有限责任公司 | 国药准字H20234622 | 2023/12/13 | 0.36g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 杨凌科森生物制药有限责任公司 | 杨凌科森生物制药有限责任公司 | 国药准字H20234627 | 2023/12/13 | 0.36g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| Amneal Pharmaceuticals of New York, LLC | Amneal Pharmaceuticals of New York, LLC | 国药准字HJ20230112 | 2023/10/12 | 0.36g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 广东九瑞科技开发有限公司 | 天津汉瑞药业有限公司 | 国药准字H20234202 | 2023/09/28 | 0.36g（按C16H28N2O4 计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏万高药业股份有限公司 | 江苏万高药业股份有限公司 | 国药准字H20234149 | 2023/09/12 | 0.36g（按C16H28N2O4 计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 石家庄四药有限公司 | 石家庄四药有限公司 | 国药准字H20233925 | 2023/07/11 | 0.36g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 广州南新制药有限公司 | 博瑞制药（苏州）有限公司 | 国药准字H20233623 | 2023/05/29 | 0.36g（按C16H28N2O4 计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 中山万汉制药有限公司 | 中山万汉制药有限公司 | 国药准字H20233375 | 2023/03/24 | 0.36g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏江丰医药科技有限公司 | 天津汉瑞药业有限公司 | 国药准字H20233382 | 2023/03/24 | 0.36g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 齐鲁制药（海南）有限公司 | 齐鲁制药（海南）有限公司 | 国药准字H20233237 | 2023/02/28 | 0.36g（按C16H28N2O4 计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 哈尔滨市康隆药业有限责任公司 | 南京海纳制药有限公司 | 国药准字H20223901 | 2022/11/30 | 0.36g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 苏州二叶制药有限公司 | 苏州二叶制药有限公司 | 国药准字H20223568 | 2022/08/10 | 0.36g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 博瑞制药（苏州）有限公司 | 博瑞制药（苏州）有限公司 | 国药准字H20223402 | 2022/06/16 | 0.36g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 广东东阳光药业有限公司 | 广东东阳光药业有限公司 | 国药准字H20223198 | 2022/04/08 | 0.36g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 宜昌东阳光长江药业股份有限公司 | 宜昌东阳光长江药业股份有限公司 | 国药准字H20223213 | 2022/04/08 | 0.36g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都倍特药业股份有限公司 | 成都倍特药业股份有限公司 | 国药准字H20223147 | 2022/03/22 | 0.36g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| Hetero Labs Limited | Hetero Labs Limited | 国药准字HJ20210075 | 2021/10/26 | 12.5ml∶75mg（按C16H28N2O4计）。（每瓶含奥司他韦360mg，加水55ml可配制成60ml供口服的混悬液。配制后，相当于每1ml混悬液含奥司他韦6mg。） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 北京诚济制药股份有限公司 | 北京诚济制药股份有限公司 | 国药准字H20234558 | 2023/11/28 | 0.36g（按C16H28N2O4计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 39 distinct approval numbers and 39 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 北京斯利安药业有限公司 | 国药准字H20249550 | 0.36g(按C₁₆H₂₈N₂O₄计) | Category B (乙) | XJ05AHA218X006010100011 | NHSA |
| 广州南新制药有限公司 | 国药准字H20233623 | 0.36g(按C16H28N2O4计) | Category B (乙) | XJ05AHA218X006010100407 | NHSA |
| 华润三九医药股份有限公司 | 国药准字H20249097 | 0.36g(按C₁₆H₂₈N₂O₄ 计) | Category B (乙) | XJ05AHA218X006010100474 | NHSA |
| 国药集团致君(深圳)制药有限公司 | 国药准字H20253530 | 0.36g(按C₁₆H₂₈N₂O₄ 计) | Category B (乙) | XJ05AHA218X006010100555 | NHSA |
| 江苏万高药业股份有限公司 | 国药准字H20234149 | 0.36g(按C₁₆H₂₈N₂O₄计) | Category B (乙) | XJ05AHA218X006010101503 | NHSA |
| 江苏正大清江制药有限公司 | 国药准字H20244748 | 0.36g(按C₁₆H₂₈N₂O₄计) | Category B (乙) | XJ05AHA218X006010101522 | NHSA |
| 苏州二叶制药有限公司 | 国药准字H20223568 | 0.36g(按C₁₆H₂₈N₂O₄计) | Category B (乙) | XJ05AHA218X006010101651 | NHSA |
| 成都倍特药业股份有限公司 | 国药准字H20223147 | 0.36g(按C₁₆H₂₈N₂O₄计) | Category B (乙) | XJ05AHA218X006010102013 | NHSA |
| 四川子仁制药有限公司 | 国药准字H20244155 | 0.36g(以C₁₆H₂₈N₂O₄计) | Category B (乙) | XJ05AHA218X006010102277 | NHSA |
| 杨凌科森生物制药有限责任公司 | 国药准字H20234627 | 0.36g(按C₁₆H₂₈N₂O₄计) | Category B (乙) | XJ05AHA218X006010102544 | NHSA |
| 保定天浩制药有限公司 | 国药准字H20253060 | 0.36g(按C₁₆H₂₈N₂O₄计) | Category B (乙) | XJ05AHA218X006010102551 | NHSA |
| 石家庄四药有限公司 | 国药准字H20233925 | 0.36g(按C16H28N2O4计) | Category B (乙) | XJ05AHA218X006010102763 | NHSA |
| 遂成药业股份有限公司 | 国药准字H20253902 | 0.36g(按C₁₆H₂₈N₂O₄ 计) | Category B (乙) | XJ05AHA218X006010103204 | NHSA |
| 哈尔滨华瑞生化药业有限责任公司 | 国药准字H20234622 | 0.36g(按C₁₆H₂₈N₂O₄计) | Category B (乙) | XJ05AHA218X006010103634 | NHSA |
| 哈药集团制药六厂 | 国药准字H20255698 | 0.36g(按C₁₆H₂₈N₂O₄计) | Category B (乙) | XJ05AHA218X006010103710 | NHSA |
| 山东新华制药股份有限公司 | 国药准字H20256303 | 0.36g(按C₁₆H₂₈N₂O₄计) | Category B (乙) | XJ05AHA218X006010104187 | NHSA |
| 浙江普洛康裕制药有限公司 | 国药准字H20256273 | 0.36g(按C₁₆H₂₈N₂O₄计) | Category B (乙) | XJ05AHA218X006010104685 | NHSA |
| 福建省闽东力捷迅药业股份有限公司 | 国药准字H20254807 | 0.36g(按C₁₆H₂₈N₂O₄算) | Category B (乙) | XJ05AHA218X006010104799 | NHSA |
| 海南葫芦娃药业集团股份有限公司 | 国药准字H20255455 | 0.36g(按C₁₆H₂₈N₂O₄计) | Category B (乙) | XJ05AHA218X006010105789 | NHSA |
| 海南斯达制药有限公司 | 国药准字H20243816 | 0.36g(按C₁₆H₂₈N₂O₄计) | Category B (乙) | XJ05AHA218X006010105816 | NHSA |
| 齐鲁制药(海南)有限公司 | 国药准字H20233237 | 0.36g(按C₁₆H₂₈N₂O₄ 计) | Category B (乙) | XJ05AHA218X006010105847 | NHSA |
| 广东东阳光药业股份有限公司 | 国药准字H20223198 | 0.36g(按C16H28N2O4计) | Category B (乙) | XJ05AHA218X006010106988 | NHSA |
| 中山万汉制药有限公司 | 国药准字H20233375 | 0.36g(按C16H28N2O4计) | Category B (乙) | XJ05AHA218X006010109920 | NHSA |
| Hetero Labs Limited | 国药准字HJ20210075 | 0.36g(按C16H28N2O4计) | Category B (乙) | XJ05AHA218X006010179426 | NHSA |
| 博瑞制药(苏州)有限公司 | 国药准字H20223402 | 0.36g(按C16H28N2O4计) | Category B (乙) | XJ05AHA218X006010180081 | NHSA |
| 哈尔滨市康隆药业有限责任公司 | 国药准字H20223901 | 0.36g(按C₁₆H₂₈N₂O₄计) | Category B (乙) | XJ05AHA218X006010180537 | NHSA |
| 江苏诺泰澳赛诺生物制药股份有限公司 | 国药准字H20244919 | 0.36g(按C₁₆H₂₈N₂O₄计) | Category B (乙) | XJ05AHA218X006010180539 | NHSA |
| 宜昌东阳光长江药业股份有限公司 | 国药准字H20223213 | 0.36g(按C16H28N2O4计) | Category B (乙) | XJ05AHA218X006010180955 | NHSA |
| 北京诚济制药股份有限公司 | 国药准字H20234558 | 0.36g(按C₁₆H₂₈N₂O₄计) | Category B (乙) | XJ05AHA218X006010182209 | NHSA |
| 乐普制药科技有限公司 | 国药准字H20243080 | 0.36g(按C₁₆H₂₈N₂O₄计) | Category B (乙) | XJ05AHA218X006010182919 | NHSA |
| 浙江普利药业有限公司 | 国药准字H20244240 | 0.36g(按C₁₆H₂₈N₂O₄计) | Category B (乙) | XJ05AHA218X006010182922 | NHSA |
| 山东百诺医药股份有限公司 | 国药准字H20263971 | 0.36g(按C₁₆H₂₈N₂O₄计) | Category B (乙) | XJ05AHA218X006010183011 | NHSA |
| 福建省宝诺医药研发有限公司 | 国药准字H20253138 | 0.36g(按C₁₆H₂₈N₂O₄计) | Category B (乙) | XJ05AHA218X006010183544 | NHSA |
| 恒昌(广州)新药研究有限公司 | 国药准字H20254584 | 0.36g(按C₁₆H₂₈N₂O₄计) | Category B (乙) | XJ05AHA218X006010183569 | NHSA |
| 江苏江丰医药科技有限公司 | 国药准字H20233382 | 0.36g( 按C₁₆H₂₈N₂O₄ 计) | Category B (乙) | XJ05AHA218X006010183817 | NHSA |
| 山西同达药业有限公司 | 国药准字H20253829 | 0.36g(按C₁₆H₂₈N₂O₄计) | Category B (乙) | XJ05AHA218X006010184219 | NHSA |
| 浙江高跖医药科技股份有限公司 | 国药准字H20244434 | 0.36g(按C₁₆H₂₈N₂O₄计) | Category B (乙) | XJ05AHA218X006010184221 | NHSA |
| 江苏加友药业集团有限公司 | 国药准字H20253775 | 0.36g (按C₁₆H₂₈N₂O₄计) | Category B (乙) | XJ05AHA218X006010184962 | NHSA |
| 济南同路医药科技发展有限公司 | 国药准字H20253826 | 0.36g(按C16H28N2O4计) | Category B (乙) | XJ05AHA218X006010185067 | NHSA |
| 苏州二叶制药有限公司 | 国药准字H20223568 | 0.36g(按C₁₆H₂₈N₂O₄计) | Category B (乙) | XJ05AHA218X006010201651 | NHSA |
| 四川子仁制药有限公司 | 国药准字H20244155 | 0.36g(以C₁₆H₂₈N₂O₄计) | Category B (乙) | XJ05AHA218X006010202277 | NHSA |
| Hetero Labs Limited | 国药准字HJ20210075 | 0.36g(按C16H28N2O4计) | Category B (乙) | XJ05AHA218X006010279426 | NHSA |
| 山西同达药业有限公司 | 国药准字H20253829 | 0.36g(按C₁₆H₂₈N₂O₄计) | Category B (乙) | XJ05AHA218X006010284219 | NHSA |
| 山西同达药业有限公司 | 国药准字H20253829 | 0.36g(按C₁₆H₂₈N₂O₄计) | Category B (乙) | XJ05AHA218X006010384219 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 2 filings and 2 distinct first applicants.
Generic 2
New generic filings in 2026
Loaded records: 2 filings and 2 distinct first applicants.
API registrations
Non-component matches: 33 companies with A status and 5 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 磷酸奥司他韦 | 白云山东泰商丘药业有限公司 | Y20260000131 | I | Exact ingredient | 2026/03/20 | CDE |
| 磷酸奥司他韦 | 吉林敖东洮南药业股份有限公司 | Y20250001476 | I | Exact ingredient | 2026/01/09 | CDE |
| 磷酸奥司他韦 | 新天地药业股份有限公司 | Y20250001153 | I | Exact ingredient | 2025/11/07 | CDE |
| 磷酸奥司他韦 | 河北华晨药业集团有限公司 | Y20240001127 | A | Exact ingredient | 2026/03/16 | CDE |
| 磷酸奥司他韦 | 新乡双鹭药业有限公司 | Y20240000651 | A | Exact ingredient | 2026/05/07 | CDE |
| 磷酸奥司他韦 | 万洋衡水制药有限公司 | Y20240000564 | A | Exact ingredient | 2026/09/29 | CDE |
| 磷酸奥司他韦 | 珠海海瑞德制药有限公司 | Y20240000421 | A | Exact ingredient | 2026/01/07 | CDE |
| 磷酸奥司他韦 | 深圳市海滨制药有限公司 | Y20240000379 | A | Exact ingredient | 2026/04/01 | CDE |
| 磷酸奥司他韦 | 浙江华海药业股份有限公司 | Y20230000607 | A | Exact ingredient | 2025/02/07 | CDE |
| 磷酸奥司他韦 | 遂成药业股份有限公司 | Y20230000528 | A | Exact ingredient | 2024/09/30 | CDE |
| 磷酸奥司他韦 | 乳源东阳光药业有限公司 | Y20230000225 | A | Exact ingredient | 2025/12/05 | CDE |
| 磷酸奥司他韦 | 福建省福抗药业股份有限公司 | Y20230000154 | A | Exact ingredient | 2025/10/16 | CDE |
| 磷酸奥司他韦 | 北京金城泰尔制药有限公司 | Y20220001282 | A | Exact ingredient | 2025/07/23 | CDE |
| 磷酸奥司他韦 | 遂成药业股份有限公司 | Y20220001053 | I | Exact ingredient | 2023/04/25 | CDE |
| 磷酸奥司他韦 | 苏州正济药业有限公司 | Y20220000844 | A | Exact ingredient | 2025/03/05 | CDE |
| 磷酸奥司他韦 | 浙江普洛康裕制药有限公司 | Y20220000876 | A | Exact ingredient | 2025/07/28 | CDE |
| 磷酸奥司他韦 | 天方药业有限公司 | Y20220000727 | A | Exact ingredient | 2026/05/20 | CDE |
| 磷酸奥司他韦 | 湖南欧亚药业有限公司 | Y20220000508 | A | Exact ingredient | 2025/09/11 | CDE |
| 磷酸奥司他韦 | 海正药业南通有限公司 | Y20220000102 | A | Exact ingredient | 2024/02/28 | CDE |
| 磷酸奥司他韦 | 杭州福斯特药业有限公司 | Y20220000223 | A | Exact ingredient | 2024/05/21 | CDE |
| 磷酸奥司他韦 | 重庆瑞泊莱制药有限公司 | Y20220000017 | A | Exact ingredient | 2025/03/11 | CDE |
| 磷酸奥司他韦 | INIST ST Co., Ltd. | Y20210001077 | A | Exact ingredient | 2024/03/25 | CDE |
| 磷酸奥司他韦 | 重庆圣华曦药业股份有限公司 | Y20210000702 | A | Exact ingredient | 2025/12/17 | CDE |
| 磷酸奥司他韦 | SOLARA ACTIVE PHARMA SCIENCES LIMITED | Y20210000504 | A | Exact ingredient | 2024/02/08 | CDE |
| 磷酸奥司他韦 | Innovare Labs Private Limited | Y20210000432 | A | Exact ingredient | 2023/08/01 | CDE |
| 磷酸奥司他韦 | 湖南九典宏阳制药有限公司 | Y20210000419 | A | Exact ingredient | 2025/01/11 | CDE |
| 磷酸奥司他韦 | 南京海鲸药业股份有限公司 | Y20210000418 | A | Exact ingredient | 2024/03/26 | CDE |
| 磷酸奥司他韦 | 上海迪赛诺化学制药有限公司 | Y20210000082 | A | Exact ingredient | 2024/04/12 | CDE |
| 磷酸奥司他韦 | 中山万汉制药有限公司 | Y20200001194 | A | Exact ingredient | 2024/10/31 | CDE |
| 磷酸奥司他韦 | 杨凌吉泰药业有限公司 | Y20200000789 | A | Exact ingredient | 2023/03/24 | CDE |
| 磷酸奥司他韦 | 江苏诺泰澳赛诺生物制药股份有限公司 | Y20200000736 | A | Exact ingredient | 2026/10/11 | CDE |
| 磷酸奥司他韦 | Matrix Pharmacorp Private Limited | Y20200000772 | A | Exact ingredient | 2026/08/22 | CDE |
| 磷酸奥司他韦 | Laurus Labs Limited | Y20190000837 | A | Exact ingredient | 2024/07/18 | CDE |
| 磷酸奥司他韦 | 宜昌东阳光长江药业股份有限公司 | Y20190009757 | A | Exact ingredient | 2023/03/24 | CDE |
| 磷酸奥司他韦 | 博瑞制药（苏州）有限公司 | Y20180001370 | A | Exact ingredient | 2026/05/08 | CDE |
| 磷酸奥司他韦 | MSN Pharmachem Private Limited | Y20190000398 | A | Exact ingredient | 2026/05/20 | CDE |
| 磷酸奥司他韦 | Raks Pharma Pvt.Ltd. | Y20190000606 | I | Exact ingredient | 2019/08/14 | CDE |
| 磷酸奥司他韦 | Hetero Labs Limited | Y20180001225 | A | Exact ingredient | 2026/10/12 | CDE |
| 磷酸奥司他韦 | 宜昌东阳光长江药业股份有限公司 | Y20170001954 | A | Exact ingredient | 2026/08/07 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/10/30No longer listed under review
宜昌人福药业有限责任公司
CYHS2500067
Fact date: 2026/10/30 · Site observation date: 2026/10/30
Accepted: 2025/01/06
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ -
2026/09/04Accepted
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Oseltamivir Phosphate For Oral Suspension
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy